FAQ

Marija D. Zdravković

Suggest Changes
G. Aboagye-Mathiesen27
P. Ebbesen27
Darko Zdravković20
H. Hager18
Mirjana Krotin18
32Lisbeth V. Jacobsen
32Anette K. Olsen
31Peter Ebbesen
29Anne Flint
26Steen H. Ingwersen

Filter Results:

  • Full text PDF available (25)

Publication Year

1968
2018
  • This year (16)
  • Last 5 years (44)
  • Last 10 years (66)

Publication Type

Co-author

Journals and Conferences

Learn More
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in…
AIM To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body… (More)
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat…
AIM The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D). … (More)
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
AIMS To evaluate dose-response efficacy and safety of once-daily human GLP-1 analog liraglutide in Japanese subjects with type 2 diabetes. METHODS Patients (226, treated with diet with/without… (More)